MFDS Approves Treatment for Myasthenia Gravis
Approval of Imported Rare Drug Vibgatju
Expanding Treatment Options for Myasthenia Gravis Patients
The Ministry of Food and Drug Safety announced on the 20th that it has approved the rare drug 'Vibgatju (efgatigimod alpha)' used to treat adult patients with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies.
Vibgatju works by blocking the binding of autoantibody IgG to the neonatal Fc receptor (FcRn), promoting the degradation of autoantibodies, thereby showing therapeutic effects in patients with myasthenia gravis mediated by autoantibodies.
This drug is the first in Korea to be approved as a therapeutic agent with a new mechanism of action that binds to FcRn. Through this approval, it is expected that the range of treatment options for adult patients with generalized myasthenia gravis will expand.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Meanwhile, the Ministry of Food and Drug Safety designated this drug as the 22nd product under the 'Global Innovative Product Fast-Track Review System' and expedited its review to ensure rapid introduction into the treatment field for patients with myasthenia gravis in Korea.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
